09:30 AM EDT, 05/31/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday that the phase 3 study assessing Trodelvy compared with docetaxel showed that it reduced the risk of death by 16% in patients with metastatic or advanced non-small cell lung cancer.

The company said that in the study, adverse events that were at least grade 3 were lower among patients receiving Trodelvy compared with docetaxel.

Gilead Sciences ( GILD ), which previously announced that the study didn't meet the primary endpoint of overall survival, said that detailed results from the study will be presented at the American Society of Clinical Oncology Annual Meeting.

The company's shares were down 2% in premarket activity.

Price: 62.80, Change: -1.28, Percent Change: -2.00